In 2003, Wei and co-workers reported the isolation and structural elucidation of the polygalolides A (1) and B (2) obtained from Polygala fallax Hemsl., a medicinal plant from which extracts are used as tonics and antihepatitis drugs in China.[1] The structure and relative configuration of the polygalolides were determined on the basis of NMR spectroscopic data. However, the issue of the absolute stereochemistry of the molecules has not been resolved. The structural complexity of these molecules, which include an unprecedented trioxatetracyclic ring system and contiguous quaternary stereogenic centers at C2 and C8, poses a considerable synthetic challenge. Herein, we describe the first total synthesis of (À)-polygalolides A (1) and B (2). The synthesis takes advantage of a transformation consisting of a tandem carbonyl ylide formation/1,3-dipolar cycloaddition, which has been extensively studied, especially in the research group of Padwa. [2][3][4][5] Our retrosynthetic analysis of the polygalolides is illustrated in Scheme 1. We elected to introduce the arylmethylidene moiety at a late stage in the synthesis, and the scission of the lactone ring provided 3 as a common intermediate. The tricyclic compound 3 was assumed to arise from an intramolecular 1,3-dipolar cycloaddition of carbonyl ylide 5, generated from a-diazoketone 6 in the presence of a Rh II catalyst. Compound 6 arises from homologation of the tert-butyl ester 7, which would be elaborated from the known alcohol 8, [6] which in turn can readily be obtained from d-arabinose.We initiated the synthesis by alkylating alcohol 8 with (Z)-1-bromo-4-(tert-butyldiphenylsilyl)oxy-2-butene [7] to provide the allyl ether 9 in 98 % yield (Scheme 2). The oxidative hydrolysis of the dithioacetal with iodine was followed by oxidation with NaClO 2 and esterification with (Boc) 2 O[8] to give tert-butyl ester 10 in 70 % yield over three steps. Catalytic hydrogenation of alkene 10 provided the TBDPS ether 11 in 95 % yield, and 11 was then treated with Bu 4 NF in the presence of AcOH to give alcohol 12 in 96 % yield. Installation of the C2=C3 bond was accomplished by employing a modification of the procedure reported by Ogasawara and co-workers, [9] and subsequent reduction with NaBH 4 gave alcohol 13 in 81 % yield over both steps. A two-step sequence involving mesylation and nucleophilic substitution with pmethoxyphenol was used to convert the allyl alcohol 13 into the PMP ether 14 in 78 % overall yield. The acetonide was Scheme 1. Retrosynthetic analysis of polygalolides A and B. PMP = p-methoxyphenyl, TBDPS = tert-butyldiphenylsilyl.
Sphingosine 1-phosphate (S1P) functions as a ligand for the S1P/EDG family receptors. For years, intracellular signaling roles for S1P have also been suggested, especially in cell proliferation. Now, we have generated several mouse F9 embryonic carcinoma cell lines varying in expression of the S1P-degrading enzyme, S1P lyase (SPL) and/or sphingosine kinase (SPHK1). All these cell lines accumulated S1P compared to the wild-type F9 cells, but the amounts varied. We investigated the ability of these cells to proliferate under low serum conditions, as measured by a thymidine uptake assay. Although F9 cells over-expressing SPHK1 did exhibit enhanced DNA synthesis, other S1P-accumulating cells ( SPL -null cells and SPL -null cells over-expressing SPHK1) did not. The overproduction of both SPL and SPHK1 resulted in the most striking mitogenic effect. Moreover, nM concentrations of sphingosine (or dihydrosphingosine) stimulated DNA synthesis in an SPL -dependent manner. These results indicate that products by the SPL pathway, not S1P itself, function in mitogenesis.
Inhibition of glucosylceramide synthase (GCS) is a major therapeutic strategy for Gaucher’s disease and has been suggested as a potential target for treating Parkinson’s disease. Herein, we report the discovery of novel brain-penetrant GCS inhibitors. Assessment of the structure–activity relationship revealed a unique pharmacophore in this series. The lipophilic ortho-substituent of aromatic ring A and the appropriate directionality of aromatic ring B were key for potency. Optimization of the absorption, distribution, metabolism, elimination, toxicity (ADMETox) profile resulted in the discovery of T-036, a potent GCS inhibitor in vivo. Pharmacophore-based scaffold hopping was performed to mitigate safety concerns associated with T-036. The ring opening of T-036 resulted in another potent GCS inhibitor with a lower toxicological risk, T-690, which reduced glucosylceramide in a dose-dependent manner in the plasma and cortex of mice. Finally, we discuss the structural aspects of the compounds that impart a unique inhibition mode and lower the cardiovascular risk.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.